375 related articles for article (PubMed ID: 30587399)
1. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L
Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093
[TBL] [Abstract][Full Text] [Related]
3. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Yang B; Qin A; Zhang K; Ren H; Liu S; Liu X; Pan X; Yu G
Oncol Res; 2017 Nov; 25(9):1601-1606. PubMed ID: 28474575
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
6. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
8. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Tong B; Xu Y; Zhao J; Chen M; Zhong W; Xing J; Wang M
Thorac Cancer; 2018 May; 9(5):640-645. PubMed ID: 29582563
[TBL] [Abstract][Full Text] [Related]
10. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
11. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
12. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Okamoto I; Morita S; Tashiro N; Imamura F; Inoue A; Seto T; Yamamoto N; Ohe Y; Nakagawa K; Fukuoka M
Lung Cancer; 2018 Mar; 117():14-19. PubMed ID: 29496250
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.
Yang B; Zheng D; Zeng Υ; Qin A; Gao J; Yu G
J BUON; 2018; 23(4):1077-1081. PubMed ID: 30358214
[TBL] [Abstract][Full Text] [Related]
14. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
15. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
17. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
Hsu CL; Tsai TH; Huang CK; Yang CY; Liao WY; Ho CC; Ruan SY; Chen KY; Shih JY; Yang PC
Lung Cancer; 2021 Jun; 156():50-58. PubMed ID: 33894494
[TBL] [Abstract][Full Text] [Related]
18. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
[TBL] [Abstract][Full Text] [Related]
19. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F; Hoffarth S; Worm K; Cortes-Incio D; Gauler TC; Köhler J; Herold T; Schmid KW; Freitag L; Kasper S; Schuler M
PLoS One; 2014; 9(1):e85350. PubMed ID: 24465542
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]